Fibrinolysis and COVID-19: A plasmin paradox

82Citations
Citations of this article
150Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The COVID-19 pandemic has provided many challenges in the field of thrombosis and hemostasis. Among these is a novel form of coagulopathy that includes exceptionally high levels of D-dimer. D-dimer is a marker of poor prognosis, but does this also imply a causal relationship? These spectacularly raised D-dimer levels may actually signify the failing attempt of the fibrinolytic system to remove fibrin and necrotic tissue from the lung parenchyma, being consumed or overwhelmed in the process. Indeed, recent studies suggest that increasing fibrinolytic activity might offer hope for patients with critical disease and severe respiratory failure. However, the fibrinolytic system can also be harnessed by coronavirus to promote infectivity and where antifibrinolytic measures would also seem appropriate. Hence, there is a clinical paradox where plasmin formation can be either deleterious or beneficial in COVID-19, but not at the same time. Hence, it all comes down to timing.

Cite

CITATION STYLE

APA

Medcalf, R. L., Keragala, C. B., & Myles, P. S. (2020). Fibrinolysis and COVID-19: A plasmin paradox. Journal of Thrombosis and Haemostasis, 18(9), 2118–2122. https://doi.org/10.1111/jth.14960

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free